How much does one dose of Teclistamab-cqyv cost?

Teritusumab (Teclistamab-cqyv) is a breakthrough bispecific antibody drug designed to treat relapsed or refractory multiple myeloma (RRMM). Its innovative mechanism and unique target determine its high value in clinical treatment, and its price has become a common focus among patients and the medical community. According to the current quotation information in overseas markets, the price of the European version of the original teritusumab is relatively high. The price of the 30mg/3ml specification is about more than 10,000 yuan, while the higher dosage of 153mg/1.7ml (90mg/ml) can be sold for more than 50,000 yuan per box. The specific price will fluctuate due to factors such as exchange rate changes, import channels, hospital markup policies, etc. Therefore, when purchasing specific drugs, the actual market quotation must prevail.

At present, in mainland China, although teritusumab has been approved and entered the market, due to its short time on the market, it does not have clear coverage in the medical insurance catalog, the price has not yet been publicly unified, and there is no large-scale commercial channel for public sales. Therefore, most drug purchases must rely on overseas direct procurement. It should be noted that no generic drugs or biosimilars of teritusumab have been approved for marketing, which means that patients have fewer channels to choose from and the price is difficult to drop. In addition, since the drug is an injectable biological agent and needs to be administered in stages according to the course of treatment, the price of a single drug is only a part of the overall treatment cost, and the total cost of long-term treatment may be much higher than initial estimates.

Judging from overseas medication trends, although teritusumab is expensive, it still shows a good response rate in patients with RRMM who have failed multiple standard treatments , which makes its cost-effectiveness of practical significance in specific groups of people. Currently, some patients choose to obtain the original European version of teritusumab through professional third-party drug service platforms.

Reference materials:https://www.tecvayli.com/